Professional Documents
Culture Documents
PRC Ple Review 021318
PRC Ple Review 021318
E
H
at equilibrium A
steady rate
A
H
E
E
There are environmental There are environmental
changes that affect the agent. changes that affect the host.
Health and Disease
Health and Disease
Health and Disease
Quaternary
Prevention
Tertiary
Prevention - Late
Secondary Pathogenesis
Prevention - Early • Disability
Primary Pathogenesis Limitation*
Prevention - • Early Diagnosis • Rehabilitation
Primordial Prepathogenesis (Screening)
Prevention • Health • Prompt
Promotion Treatment
• Specific
Protection
Health and Disease
Primordial Quaternary
Prevention Prevention
• avoid the emergence • set of health activities
and establishment of to mitigate or avoid
the social, economic, the consequences of
and cultural patterns unnecessary or
of living that are excessive intervention
known to contribute of the health system
to an elevated risk of • to avoid patient over
disease diagnosis and
overtreatment
Health and Disease
PRC Sample Exam:
Rice and
Alternatives:
33%
Vegetables:
33%
Health and Disease
Health and Disease
Health and Disease
Health and Disease
PRC Sample Exam:
Sample
Risk
Risk
Population factor;
factor;
No
Disease
disease
No risk No risk
factor; factor;
Disease No disease
Sample Larger
with disease population
Risk Risk with disease
factor factor Cases
present absent
Sample Larger
without disease population
Risk Risk without disease
factor factor Controls
present absent
FIGURE 8.2. I n a case–control study, the investigator (a) selects a sample from a population
with the disease (cases), (b) selects a sample from a population at risk that is free of the disease
(controls), and (c) measures predictor variables.
Research Methods
Case-Control Study and the Odds Ratio (OR)
(+) Disease = (-) Disease =
Cases Controls
(+) Exposure
A B
(-) Exposure
C D
AD
OR = ------
BC
Research Methods
Interpretation of OR:
• OR = 1: risk factor is not related with disease
• OR > 1: risk factor is positively related with
disease
• OR < 1: risk factor is negatively related with
disease
Conclusion Formulation:
• Among patients with “outcome,” there is …
Research Methods
98 Study Designs
Cohort Study, Concurrent
THE PRESENT THE FUTURE
Population
Risk factor No
Disease
present disease
Risk factor No
Disease
absent disease
Sample
FIGURE 7.1. I n a prospective cohort study, the investigator (a) selects a sample
from the population (the dotted line signifies its large and undefined size)
(b) measures the predictor variables (in this case whether a dichotomous risk
factor is present [shaded]), and (c) measures the outcome variables during
follow-up (in this case whether a disease occurs [outlined in bold]).
RETROSPECTIVE COHORT STUDIES
Research
Structure
Methods
Thedesign of aretrospectivecohort study(Fig. 7.2) differsfrom that of aprospective
one in that the assembly of the cohort, baseline measurements, and follow-up have
Cohort Study, Non-Concurrent
THE PAST THE PRESENT
Risk factor No
Disease
present disease
Population
Risk factor No
absent Disease
Sample disease
A / (A + B)
RR = -----------------
C / (C+ D)
Research Methods
Interpretation of RR:
• RR = 1: risk factor is not related with disease
• RR > 1: risk factor is positively related with
disease
• RR < 1: risk factor is negatively related with
disease
Conclusion Formulation:
• Among patients with “risk factor”, there is …
Research Methods
Cross-Sectional Study, Analytical
Interpretation of Prevalence Rate Ratio (PRR)
and Prevalence Odds Ratio (POR):
AD A / (A + B)
POR = ----- PRR = --------------
BC C / (C + D)
Random Sampling
• Random sampling helps to ensure external
validity because it seeks to ensure a
representative sample of people.
Research Methods
Experimental Study / Trial
Research Methods
Quasi-Experimental Trial – Time Series
Research Methods
Quasi-Experimental Trial – Cross-Over Design
Research Methods
Epidemiology Research Study Designs
C. Other Designs – Pharmacoepidemiology /
Pharmacoeconomics
1. Cost Effectiveness Analysis
2. Cost Benefit Analysis
3. Cost Utilization Study
4. Cost Minimization Study
Research Methods
Epidemiology Research Study Designs
D. Mixed Methods Design – Qualitative
Study
1. Ethnography
2. Phenomenology
3. Grounded Theory
4. Participatory Action Research
5. Case Study
Pharmacoeconomics
• Cost Effectiveness Analysis provides a way of
comparing different proposed solutions in terms
of the most appropriate measurement units.
death / mortality
disease / morbidity
costs
longevity
disease-free time
savings
Pharmacoeconomics
• Cost Effectiveness Analysis involves a more
comprehensive look at drug costs. While cost is
measured in monetary terms, effectiveness is
determined independently and may be
measured in terms of a clinical outcome
such as number of lives saved (i.e., NNT),
complications prevented or diseases cured.
• Cost Effectiveness Analysis thus measures
the incremental cost of achieving an incremental
health benefit expressed as a particular health
outcome that varies according to the indication
for the drug.
Pharmacoeconomics
• Cost Benefit Analysis measures the costs and
the benefits of a proposed course of action in
terms of the same units, usually monetary units
such as dollars / pesos.
• Incorporating concepts such as the dollar value
of life, suffering, and the quality of life into such
an analysis is difficult. Cost Benefit Analysis
is useful, however, if a particular budgetary
entity (e.g., government or business) is trying to
determine whether the investment of resources
in health would save money in the long run.
Pharmacoeconomics
• Cost Benefit Analysis is used to value both
incremental costs and outcomes in monetary
terms and therefore allows a direct calculation of
the net monetary cost of achieving a health
outcome. A gain in life-years (survival) may
be regarded as the cost of the productive value
to society of that life-year using, for example,
the average wage.
Pharmacoeconomics
• The methods for valuing gains in quality of life
include techniques such as willingness to
pay, where the amount that individuals would
be willing to pay for a quality-of-life benefit is
assessed. However, the techniques used to
value health outcomes in monetary terms
remain somewhat controversial, with the result
that Cost Benefit Analysis is so far not widely
used in pharmacoeconomic analyses.
Pharmacoeconomics
• A subtype of Cost Effectiveness Analysis is Cost
Utility Analysis, which has the outcome of the
cost / quality-adjusted life year, also called the
cost-effectiveness ratio (CER).
• A recent comparison of the CER of various
preventive measures with treatments for existing
conditions found that both preventive and
curative measures span the cost effectiveness
spectrum; both can be cost-saving, favorable, or
unfavorable.
Pharmacoeconomics
• Cost Utility Analysis expresses the value for
money in terms of a single type of health
outcome. The CER in this case is usually
expressed as the incremental cost to gain an
extra quality-adjusted life-year (QALY).
This approach incorporates both increases in
survival time (extra life-years) and changes
in quality of life (with or without increased
survival) into one measure.
Pharmacoeconomics
• An increased quality of life is expressed as
a utility value on a scale of 0 (dead) to one
(perfect quality of life). An increased duration
of life of one year (without change in quality of
life), or an increase in quality of life from 0.5 to
0.7 utility units for five years, would both result
in a gain of one QALY. This allows for easy
comparison across different types of
health outcome, but still requires value
judgments to be made about increases in the
quality of life (utility) associated with different
health outcomes.
Pharmacoeconomics
• The use of incremental cost utility ratios enables
the cost of achieving a health benefit by
treatment with a drug to be assessed
against similar ratios calculated for other
health interventions (e.g., surgery or
screening by mammography). It therefore
provides a broader context in which to make
judgments about the value for money of using a
particular drug.
Pharmacoeconomics
• Cost Minimization Analysis is a method of
calculating drug costs to project the least
costly drug or therapeutic modality. Cost
minimization also reflects the cost of
preparing and administering a dose. This
method of cost evaluation is the one used most
often in evaluating the cost of a specific drug.
Cost minimization can only be used to compare
two products that have been shown to be
equivalent in dose and therapeutic effect.
Pharmacoeconomics
• Cost Minimization Analysis is most useful for
comparing generic and therapeutic
equivalents. In many cases, there is no
reliable equivalence between two products and if
therapeutic equivalence cannot be
demonstrated, then Cost Minimization Analysis is
inappropriate.
Pharmacoepidemiology
DISABILITY ADJUSTED LIFE YEARS (DALY)
and QUALITY ADJUSTED LIFE YEARS (QALY)
are both measurements used in order to weigh the
cost per healthy unit measure.
• Indirect Costs
reflect economic value of health state consequences (e.g., work
absenteeism, lost productivity, premature death)
• Intangible Costs
value of decreased enjoyment of life because of illness
Pharmacoepidemiology
Direct Medical Costs Direct Non-Medical
medical consultations Costs
and clinic visits transportation costs
drugs and medicine services of informal
hospital admissions caregivers
diagnostics and
ancillary services:
laboratory tests and
imaging studies
equipment and
medical supplies
Pharmacoeconomics
PRC Sample Exam:
Level of
Alert
Time
Evidence Based Medicine
• Evidence Based Medicine (EBM) refers to
the judicious use of current best evidence in
making decisions about the care of individual
patients.
• Evidence Based Medicine (EBM) integrates a
medical practitioner’s own clinical experience or
expertise with the results of medical research
into clinical practice.
Evidence Based Medicine
patient
clinical dilemma /
question on management
literature search
appraisal of literature
Inferential Statistics
• method to make generalizations and conclusions
about a target population based on results from
a sample
Biostatistics
Descriptive Analysis Inferential Analysis
• tables • estimation
• graphs – point estimate
– interval estimate
• summarizing figures
• hypothesis testing
– qualitative – mean
measures – proportion
frequency
location
– quantitative
measures
central tendency
dispersion
Biostatistics
Types of Graphs
• pie graph
• bar graph
– vertical bar graph (for quantitative variables)
– horizontal bar graph (for qualitative variables)
– component bar graph
– histogram
• line graph
• frequency polygon
• scatterplot
Biostatistics
Quantitative Variables Qualitative Variables
• variables can be • categories are simply
measured and ordered used as labels to
according to quantity or distinguish one group
amount, or whose from another and not
values can be expressed for comparison (i.e.,
numerically greater or less)
• discrete (i.e., whole
numbers / integers) or
continuous (i.e.,
fractions / decimals)
Biostatistics
Biostatistics
NATURE
GRAPH OF PURPOSE
VARIABLE
Histogram or Quantitative - graphic representation of a
Frequency Continuous frequency distribution
Polygon
Bar Graph Qualitative or comparison of absolute or
(Horizontal or Quantitative - Discrete relative counts between
Vertical) categories
Pie Qualitative breakdown of a group or total
where the number of categories
is not too many
Line Graph Time Series shows trend of data or changes
with time
Scatter Plot Quantitative correlate data between two
variables
Biostatistics
Measures of Frequency
D1 D2 D3 D4 D5 D6 D7 D8 D9
Q1 Q2 Q3
Median
Biostatistics
Measures of Central Tendency
Ungrouped Data
MEAN • average
Morbidity Rates:
• Incidence Rate
• Prevalence Rate
• Attack Rate
Public Health
INCREASED DECREASED
Prevalence Prevalence
• longer duration • shorter duration
• prolongation of life • high case fatality
without cure • decreased incidence
• increased incidence • in-migration of healthy
• in-migration of cases people
• out-migration of healthy • out-migration of cases
people • improved cure rates
• in-migration of
susceptible people
• better diagnosis /
reporting
Public Health
Mortality Rates:
• Crude Death Rate
• Specific Death Rate
• Cause Specific Death Rate
• Proportionate Mortality Rate
• Case Fatality Rate
“Believe in
yourself and
all that you
are. Know
that there is
something